Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies

Blood

Volumn 93, Issue 12, 1999, Pages 4309-4317

  Brossart, Peter ^b   Heinrich, Kathrin S ^b   Stuhler, Gernot ^b   Behnke, Lars ^b   Reichardt, Volker L ^b   Stevanovic, Stefan ^b   Muhm, Alexandra ^b   Rammensee, Hans Georg ^b   Kanz, Lothar ^b   Brugger, Wolfram ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CYTOKINE; EPITOPE; GAMMA INTERFERON; HLA ANTIGEN CLASS 2; INTERLEUKIN 12; TUMOR ANTIGEN;

ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; BREAST TUMOR; CELLULAR DISTRIBUTION; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HELPER CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; KIDNEY CARCINOMA; MAJOR HISTOCOMPATIBILITY COMPLEX; PANCREAS TUMOR; PRIORITY JOURNAL; PROTEIN DOMAIN; VACCINATION;

EID: 0033564363     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v93.12.4309.412k19_4309_4317     Document Type: Article

References (57)

1. Gendler S, Taylor-Papadimitriou J, Duhig T, Rothbard J, Burchell JA: A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats. J Biol Chem 263:12820, 1988
2. Siddiqui J, Abe M, Hayes D, Shani E, Yunis E, Kufe D: Isolation and sequencing of a cDNA coding for the human DF3 breast carcinoma-associated antigen. Proc Natl Acad Sci USA 85:2320, 1988
3. Zotter S, Hageman PC, Lossnitzer A, Mooi WJ, Hilgers J: Tissue and tumor distribution of human polymorphic epithelial mucin. Cancer Rev 11:55, 1988
4. Girling A, Bartkova J, Burchell J, Gendler S, Gillett C, Taylor-Papadimitriou J: A core protein epitope of the polymorphic epithelial mucin detected by the monoclonal antibody SM-3 is selectively exposed in a range of primary carcinomas. Int J Cancer 43:1072, 1989
5. Duperry C, Klein B, Durie BG M, Zhang X, Fourdan M, Poncelet R, Favier F, Vincent C, Brochier J, Lenoir G, Bataille R: Phenotype analysis of human myeloma cell lines. Blood 73:566, 1989
6. Mark AS, Mangkornkanok M: B-cell lymphoma marking only with anti-epithelial membrane antigen. Cancer 63:2152, 1989
7. Delsol G, Al Saati TA, Gatter KC, Gerdes J, Schwarting R, Caveriviere P, Rigal-Huguet F, Robert A, Stein H, Mason DY: Coexpression of epithelial membrane antigen (EMA), Ki-1, and interleukin-2 receptor by anaplastic large cell lymphoma. Am J Pathol 130:59, 1988
8. Apostolopoulos V, McKenzie IFC: Cellular mucins: Targets for immunotherapy. Crit Rev Immunol 14:293, 1995
9. Finn OJ, Jerome KR, Henderson RA, Pecher G, Domenech N, Magadan-Blander J, Barratt-Boyes SM: MUC1 epithelial tumor-mucin-based immunity and cancer vaccines. Immunol Rev 145:61, 1995
10. Barnd DL, Lan MS, Metzgar RS, Finn OJ: Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells. Proc Natl Acad Sci USA 86:7159, 1989
11. Jerome KR, Domenech N, Finn OJ: Tumor-specific cytotoxic T cell clones from patients with breast and pancreatic adenocarcinoma recognize EBV-immortalized B cells transfected with polymorphic epithelial mucin complementary DNA. J Immunol 151:1654, 1993
12. Ioannides CG, Fisk B, Jerome KR, Irimura T, Wharton JT, Finn OJ: Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides. J Immunol 151:3693, 1993
13. Takahashi T, Makiguchi Y, Hinoda Y, Kakiuchi H, Nakagawa N, Imai K, Yachi A: Expression of MUC1 on myeloma cells and induction of HLA-unrestricted CTL against MUC1 from a multiple myeloma patient. J Immunol 153:2102, 1994
14. Noto H, Takahashi T, Makiguchi Y, Hayashi T, Hinoda Y, Imai K: Cytotoxic T lymphocytes derived from bone marrow mononuclear cells of multiple myeloma patients recognize an undeiglycosylated form of MUC1 mucin. Int Imunol 9:791, 1997
15. Domenech N, Henderson RA, Finn OJ: Identification of an HLA-A11-restricted epitope from the tandem repeat domain of the epithelial tumor antigen mucin. J Immunol 155:4766, 1995
16. Agrawal B, Reddish MA, Longenecker BM: In vitro induction of MUC-1 peptide-specific type 1 T lymphocyte and cytotoxic T lymphocyte responses from healthy multiparous donors. J Immunol 157:2089, 1996
17. Apostolopoulos V, Haurum JS, McKenzie IF: MUC1 peptide epitopes associated with five different H-2 class I molecules. Eur J Immunol 27:2579, 1997
18. Apostolopoulos V, Karanikas V, Haurum J, McKenzie IF: Iduction of HLA-A2-restricted CTLs to the mucin 1 human breast cancer antigen. J Immunol 159:5211, 1997
19. Reddish MA, MacLean GD, Koganty RR, Kan-Mitchell J, Jones V, Mitchell MS, Longenecker BM: Anti-MUC1 class I restricted CTL in metatatic breast cancer patients immunized with a synthetic MUC1 peptide. Int J Cancer 76:817, 1998
20. Brossart P, Bevan MJ: Selective activation of Fas/FasL mediated cytotoxicity by a self-peptide. J Exp Med 183:2449, 1996
21. Houbiers JG, Nijman HW, van der Burg, SH, van der Burg SH, Drijfhout J W, Kenemans P, van de Velde CJ, Brand A, Momburg F, Kast WM, Melief CJ: In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild type p53. Eur J Immunol 23:2072, 1993
22. Janeway CA, Bottomly K: Signals and signs for lymphocytes responses. Cell 76:275, 1994
23. Steinman AM: The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 9:271, 1991
24. Steinman RM, Witmer-Pack M, Inaba K: Dendritic cells: Antigen presentation, accessory function and clinical relevance. Adv Exp Med Biol 329:1, 1993
25. Porgador A, Gilboa E: Bone-marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes. J Exp Med 182:255, 1995
26. Celluzzi CM, Mayordomo JI, Storkus WJ, Lotze MT, Falo LD: Peptide-pulsed dendritic cells induce antigen-specific, CTL-mediated protective tumor immunity. J Exp Med 183:283, 1996
27. Zitvogel L, Mayordomo JI, Tjandrawan T, DeLeo AB, Clarke MR, Lotze MT, Storkus WJ: Therapy of murine tumors with tumor peptide-pulsed dendritic cells: Dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 183:87, 1996
28. Paglia P, Chiodoni C, Rodolfo M, Colombo MP: Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J Exp Med 183:317, 1996
29. Brossait P, Goldrath AW, Butz EA, Martin S, Bevan MJ: Virus mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL. J Immunol 158:3270, 1997
30. Brossart P, Bevan MJ: Presentation of exogenous antigens on MHC class I molecules by dendritic cells: Pathway of presentation and regulation by cytokines. Blood 90:1594, 1997
31. Germain RN, Margulies DH: The biochemistry and cell biology of antigen processing and presentation. Annu Rev Immunol 11:403, 1993
32. Bevan MJ: Antigen presentation to cytotoxic T lymphocytes in vivo. J Exp Med 182:639, 1995
33. Rammensee HG, Falk K, Rötzschke O: Peptides naturally presented by MHC class I molecules. Annu Rev Immunol 11:213, 1993
34. Devenport MP, Ho Shon IAP, Hill AVS: An empirical method for the prediction of T-cell epitopes. Immunogenetics 42:392, 1995
35. Rammensee H-G, Bachmann J, Stevanovic S: MHC Ligands and Peptide Motifs. Austin, TX, Landes Bioscience, 1997
36. Sallusto F, Lanzavecchia A: Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony stimulating factor plus interleukin 4 and down regulated by tumour necrosis factor alpha. J Exp Med 179:1109, 1994
37. Zhou LJ, Tedder TF: CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells. Proc Natl Acad Sci USA 93:2588, 1996
38. Brossart P, Stuhler G, Flad T, Stevanovic S, Rammensee H-G, Kanz L, Brugger W: Her-2/neu derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. Cancer Res 58:732, 1998
39. Alexander J, Sidney J, Southwood S, Ruppert J, Oseroff C, Maewal A, Snoke K, Serra HM, Kubo RT, Sette A: Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity 1:751, 1994
40. Brummendorf TH, Kaul S, Schuhmacher J, Baum RP, Matys R, Klivenyi G, Adams S, Bastelt G: Immunoscintigraphy of human mammary carcinoma xenografts using monoclonal antibodies 12H12 and BM-2 labeled with 99m Tc and radioiodine. Cancer Res 54:4162, 1994
41. Kabayashi H, Terao T, Kawashima Y: Serum sialyl Tn as an independant predictor of poor prognosis in patients with epithelial ovarian cancer. J Clin Oncol 10:95, 1992
42. Fung PYS, Longenecker BM: Specific immunosuppressive activity of epiglycanin, a mucin like glycoprotein secreted by a mammary adenocarcinoma (TA3-HA). Cancer Res 51:1170, 1991
43. Gimmi CD, Morrison BW, Mainprice BA, Gribben JG, Boussiotis VA, Freeman GJ, Park SY, Watanabe M, Gong J, Hayes DF, Kufe DW, Nadlet LM: Breast cancer-associated antigen, DF3/MUC1, induces apoptosis of activated human T cells. Nat Med 2:1367, 1996
44. Agrawal B, Krantz MJ, Reddish MA, Longenecker M: Cancer associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2. Nat Med 4:43, 1998
45. Kotera Y, Fontenot JD, Pecher G, Metzgar RS, Finn OJ: Humoral immunity against a tandem repeat epitope of human mucin MUC1 in sera from breast, pancreatic, and colon cancer patients. Cancer Res 54:2856, 1994
46. Karanikas V, Hwang L, Pearson J, Ong CS, Apostolopoulos V, Vaughan H, Xing PX, Jamieson G, Pietersz GA, Tait B, Broadbent R, Thyme G, McKenzie IFC: Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein. J Clin Invest 100:2783, 1997
47. Agrawal B, Krantz MJ, Reddish MA, Longenecker BM: Rapid induction of primary human CD4 + and CDS + T cell responses against cancer-associated MUC1 peptide epitopes. Int Immunol 10:1907, 1998
48. Henderson RA, Michel H, Sakaguchi K, Shabanowitz J, Apella E, Hunt DF, Engelhard VH: HLA-A2.1-associated peptides from a mutant cell line: A second pathway of antigen presentation. Science 255:1264, 1992
49. Snyder HL, Yewdell J, Bennink JR: Trimming of antigenic peptides in an early secretory compartment. J Exp Med 180:2389, 1994
50. Gong J, Chen D, Kashiwaba M, Li Y, Chen L, Takeuchi H, Qu H, Rowse GJ, Gendler SJ, Kufe D: Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells. Proc Natl Acad Sci USA 95:6279, 1998
51. Cella M, Sallusto F, Lanzavecchia A: Origin, maturation and antigen presenting function of dendritic cells. Curr Opin Immunol 9:10, 1997
52. Chapuis F, Rosenzwajg M, Yagello M, Ekman M, Biberfeld P, Gluckman JC: Differentiation of human dendritic cells from monocytes in vitro. Eur J Immunol 27:431, 1997
53. Romani N, Reider D, Heuer M, Ebner S, Kampgen E, Eibl B, Niederwieser D, Schuler G: Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J Immunol Methods 196:137, 1996
54. Fisch P, Köhler G, Garbe A, Herbst B, Wider D, Kohler H, Schaefer HE, Mertelsmann R, Brugger W, Kanz L: Generation of antigen-presenting cells for soluble protein antigens ex vivo from peripheral blood CD34+ hematopoetic progenitor cells in cancer patients. Eur J Immunol 26:595, 1996
55. Bernhard H, Disis ML, Heimfeld S, Hand S, Gralow JR, Cheever MA: Generation of immunostimulatory dendritic cells from human CD34+ hematopoetic progenitor cells of the bone marrow and peripherel blood. Cancer Res 55:1099, 1995
56. Hsu FJ, Benike C, Fagnoni F, Lues TM, Czerwinski D, Taidi B, Engleman EG, Levy R: Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 2:52, 1996
57. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4:328, 1998